Clinical Trials · NCT07728383
A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity
- Phase
- Phase 4
- Recruitment status
- Recruiting
- Sponsor
- Gila Therapeutics, Inc.
- Enrollment
- 40
- Start date
- Jun 2026
- Locations
- 1 site, United States
- Primary endpoint
- Percent body weight change from baseline